George Lundberg, MD Contributing Editor at Cancer Commons

  •   George Lundberg, MD

    This CancerConnect article summarizes the latest treatment options for stage IV colorectal cancer.

    .

  •   George Lundberg, MD

    Living with ovarian cancer may require many adaptations. This respected organization can help. Learn about their comprehensive resources for patients.

    .

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    There are now many precision oncology treatments for the most common type of kidney cancer, renal cell carcinoma, which represents about 3% of all potentially lethal cancers in America. This summary from Medscape details all the traditional treatment approaches, as well as newer considerations.

    .

  •   George Lundberg, MD

    This scientific research paper published in the journal Cancer Medicine reports that the drug sorafenib has shown some effectiveness against hepatocellular carcinoma in a clinical trial, and that adding vitamin K2 enhanced that effectiveness.

    .

  •   George Lundberg, MD

    This scientific review paper published in the journal Signal Transduction and Targeted Therapy discusses recent research into newer medications that show promise as targeted therapies for some cases of primary hepatocellular carcinoma, following molecular testing.

    .

  •   George Lundberg, MD

    NCI-CONNECT shares insights from patients, caregivers, doctors, and advocates with the aim to help you manage your life—regardless of your brain cancer diagnosis.

    .

  •   George Lundberg, MD

    Ablation therapy is becoming common practice for treatment of cancer that begins in the liver. MyHealth.Alberta.ca provides information on recovery and at-home care following the procedure.

  •   George Lundberg, MD

    Memorial Sloan Kettering Cancer Center recently began recruiting patients for a phase 1 clinical trial to test a treatment in which an investigational cancer cell-killing virus called Telomelysin is directly injected into inoperable esophageal cancer tumors. Participating patients will receive this “cancer vaccine” alongside standard chemoradiation therapy.

    .

  •   George Lundberg, MD

    Immuno-Oncology News reports on the European Commission’s approval of the drug nivolumab (Opdivo) for some patients with advanced esophageal cancer.

    .

  •   George Lundberg, MD

    This article from MedPage Today discusses recent study findings demonstrating that patients with complex cases of non-small cell lung cancer can benefit from the insights of a molecular tumor board.

    .